Feb 14, 2024 / 09:00AM GMT
Operator
This call is being recorded. Welcome to the Mendus Q4-2023 presentation. (Operator Instructions) Now, I will hand the conference over to the speaker CEO, Erik Manting. Please go ahead.
Erik Manting - Mendus AB(publ)-CEO
Good morning, everyone, and thanks for joining our quarterly webcast related to the release of our Q4 and year-end numbers. I will guide you through an update of what happened in the past year and also forward looking how we will take the company in the next steps of its developments.
2023 was a transformative year for Mendus. We saw in our Phase-2 trial, the ADVANCE II trial, long-term survival in AML patients with a high-risk profile due to their measurable residual disease or MRD positive status. And that aligns with an observation which we saw in the Phase-1 trial, which we have completed and which we published last November, where also, we saw that patients, particularly the patients with a relatively low disease burden, but still with a high-risk profile based on their side of genetic tumor profile
Q4 2023 Mendus AB (publ) Earnings Call Transcript
Feb 14, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers